Previous Article | Next Article ![]()
Infection and Immunity, September 2005, p. 6179-6182, Vol. 73, No. 9
0019-9567/05/$08.00+0 doi:10.1128/IAI.73.9.6179-6182.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
and
S. Srikumaran*
Department of Veterinary and Biomedical Sciences, University of NebraskaLincoln, Lincoln, Nebraska 68583-0905
Received 5 January 2005/ Returned for modification 5 April 2005/ Accepted 20 April 2005
|
|
|---|
|
|
|---|
ß2 integrins are leukocyte-specific integrins which have a common ß subunit, CD18. The ß subunit CD18 associates with three distinct
subunits, CD11a, CD11b, and CD11c to give rise to three different ß2 integrins: CD11a/CD18 (LFA-1), CD11b/CD18 (Mac-1), and CD11c/CD18 (CR4), respectively. Both the
subunit, CD11, and the ß subunit, CD18, are type I membrane glycoproteins consisting of a short C-terminal cytoplasmic domain, a transmembrane domain, and an extracellular domain (6).
In a previous study in our laboratory, by rendering Lkt-nonsusceptible murine cells susceptible to Lkt by recombinant expression of bovine CD18, we demonstrated in a biologically relevant system that bovine CD18 is necessary and sufficient to mediate Lkt-induced cytolysis of bovine leukocytes (4). Therefore, the next logical step was to identify the Lkt binding domain on CD18, which formed the objective of this study. Although bovine and murine CD18 molecules have 80% amino acid sequence identity, Lkt does not bind to murine CD18. Alignment of amino acid sequence of bovine and murine CD18 (GenPept accession no. AAA30438 and CAA33077, respectively), by use of ClustalW and Boxshade 3.21 (Swiss Embnet servers, http://www.ch.embnet.org/software/ClustalW.html and http://www.ch.embnet.org/software/BOX_form.html), revealed that N-terminal and C-terminal regions have the most variation. Therefore, we hypothesized that the Lkt binding domain lies in the N- or C-terminal region of bovine CD18. We reasoned that chimeric CD18 made with different domains of bovine and murine CD18 should reveal the location of Lkt binding site. In this study, we used transfectant cell lines expressing bovine-murine chimeric CD18 molecules to map the Lkt binding domain on bovine CD18.
Cell lines, antibodies, and leukotoxin. P815 is a murine mastocytoma cell line which expresses murine ß2 integrin LFA-1 (CD11a/CD18). This cell line is neither lysed nor bound by Lkt. 2B2, a transfectant cell line expressing full-length bovine CD18 on the cell surface, was previously developed in our laboratory by transfecting P815 with cDNA for bovine CD18 (4). The monoclonal antibody (MAb) MM-605, previously developed in our laboratory (5), specifically binds Lkt but does not neutralize it. Fluorescein isothiocyanate (FITC)-conjugated MM-605 was used to detect Lkt binding in flow cytometry experiments. Production and affinity purification of Lkt from M. haemolytica A1 has been described by us previously (5).
Construction of bovine-murine chimeric CD18 cDNA. Bovine CD18 cDNA cloned in pBluescript SK() was obtained from Marcus Kehrli (11). Murine CD18 cDNA (13) cloned in pBluescript SK() was acquired from the American Type Culture Collection (catalog no. 63056). The nucleotide (nt) sequences of bovine and murine CD18 (GenBank accession no. M81233 and X14951, respectively) were compared to identify unique restriction sites present in both sequences at identical positions. The restriction sites BsrGI (at nt 875) and BglII (at nt 1583) were identified. Cleavage at these sites divided CD18 cDNA into three fragments containing nucleotides encoding amino acid residues 1 to 291 (fragment A), residues 292 to 527 (fragment B), and residues 528 to 770 (fragment C) (Fig. 1). We used two restriction sites in the pBluescript SK() vector, viz., SacI at nt 759 and KpnI at nt 657 for releasing the A and C fragments from the vector. The acquired murine CD18 cDNA cloned in pBluescript SK() was in the reverse orientation in the vector compared to that of the bovine CD18 cDNA clone. The murine CD18 cDNA was brought to the same orientation as that of the bovine CD18 cDNA so that fragments A, B, and C originating from restriction digestion could be exchanged with the bovine counterparts. The murine CD18 cDNA clone in pBluescript SK() with the same orientation as that of bovine CD18 cDNA was chosen to be spliced for making chimeras.
![]() View larger version (29K): [in a new window] |
FIG. 1. Construction of bovine-murine CD18 chimeric cDNA. The wild-type (wt) bovine and murine CD18 cDNAs were cut by using two unique restriction sites present in both sequences (BsrGI [at nt 875], and BglII [at nt 1583]), generating three fragments, A, B, and C. One set of three chimeric CD18 cDNAs was constructed by deleting fragment A, B, or C, from murine CD18 and inserting the corresponding fragment of bovine CD18; these chimeras were designated b291m, m291b527m, and m527b, respectively, following the nomenclature adopted by Huang et al. (7). The designation b291m indicates that residues 1 to 291 are from bovine CD18 and residues from 292 to the C terminus are from murine CD18. The designation m291b527m indicates that residues 1 to 291 are from murine CD18, residues 292 to 527 are from bovine CD18 and residue 528 to the C terminus are from murine CD18. The designation m527b indicates that residues 1 to 527 are from murine CD18 and residues from 528 to the C terminus are from bovine CD18. The chimeras b291m, m291b527m, and m527b were transfected into the murine mastocytoma cell line P815, and the resultant stable transfectant cell lines were designated 6S1, 4S1, and 2S2, respectively. Another set of three chimeras was constructed by a method opposite to the method described above, i.e., by deleting a fragment from bovine CD18 and inserting the corresponding fragment of murine CD18 (m291b, b291m527b, and b527m). Transfectant cell lines expressing this set of chimeras were not developed because of the reasons presented in the text. aa, amino acid.
|
Stable expression of bovine-murine chimeras in P815 cells. P815 cells were transfected for stable expression of bovine-murine CD18 chimeras by use of Superfect transfection agent (QIAGEN, Valencia, CA) according to the manufacturer's instructions. One stable transfectant cell line per chimera was selected for analysis of Lkt binding and lysis: 6S1 for b291m, 4S1 for m291b527m, and 2S2 for m527b.
Lkt binds to the transfectant cell line expressing bovine CD18 fragment encompassing amino acids 1 to 291. The bovine-murine chimeric transfectant cell lines 6S1, 4S1, 2S2, and the transfectant cell line 2B2 expressing the full-length bovine CD18, and the parent cells, P815, were tested for Lkt binding by flow cytometric analysis, according to procedures previously published by us (1, 4). The cells were incubated with Lkt, followed by FITC-conjugated anti-Lkt MAb MM-605. As expected, the Lkt bound to 2B2 but not to the parent cells (Fig. 2). Of the three transfectant cell lines, Lkt bound to 6S1 but not to 4S1 and 2S2, indicating that the Lkt binding domain lies within amino acids 1 to 291 of bovine CD18.
![]() View larger version (25K): [in a new window] |
FIG. 2. Lkt binds to the transfectant cell line expressing bovine CD18 fragment encompassing amino acids 1 to 291. The bovine-murine chimeric CD18 transfectant cell lines 6S1 (b291m), 4S1 (m291b527m), and 2S2 (m527b) were tested for Lkt binding by flow cytometry. The parent cell line, P815, and the previously developed transfectant cell line, 2B2, expressing the full-length bovine CD18, were used as the negative and positive controls, respectively. The cells were treated with Lkt, and the binding of Lkt to the cells was detected by treating the cells with FITC-conjugated anti-Lkt MAb MM-605. Results of one representative experiment out of three are shown.
|
![]() View larger version (27K): [in a new window] |
FIG. 3. Lkt lyses the transfectant cell line expressing bovine CD18 fragment encompassing amino acids 1 to 291. The bovine-murine chimeric CD18 transfectant cell lines 6S1 (b291m), 4S1 (m291b527m), and 2S2 (m527b) were subjected to an MTT dye reduction cytotoxicity assay with Lkt (culture supernatant at 1:4 dilution). The parent cell line, P815, and the previously developed transfectant cell line, 2B2, expressing the full-length bovine CD18, were used as the negative and positive controls, respectively. The percent cytotoxicity was calculated as follows: percent cytotoxicity = [1 (OD of toxin-treated cells/OD of untreated cells)] x 100. Results shown are the means of two independent experiments. The error bars indicate standard deviations of the means. Asterisks indicate that the values for 2B2 and 6S1 are statistically significantly greater than the value for P815, the negative control cell line (P < 0.05). Statistical analysis also revealed that the values for 2B2 and 6S1 are not significantly different from each other.
|
Present address: Influenza Branch, DVRD, NCID, Centers for Disease Control and Prevention, Mail Stop G-16, 1600 Clifton Road, Atlanta, GA 30333. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»